尾加压素Ⅱ受体拮抗剂的研究进展  

Research Progress in UrotensinⅡ Receptor Antagonist

作　　者：彭林平[1] 黄贵心[2] 

机构地区：[1]广东医学院,广东湛江524001 [2]广东医学院附属医院内分泌科,广东湛江524001

出　　处：《医学综述》2013年第20期3679-3682,共4页Medical Recapitulate

摘　　要：作为体内具有最强收缩血管能力的物质,尾加压素Ⅱ(UⅡ)及其受体(UT)组成的尾加压素系统参与多种疾病的病理生理发展过程。UⅡ/UT系统在人体内广泛分布于中枢神经系统、心血管系统、胰腺和肾脏等处。因此,UT拮抗剂被认为是治疗相关疾病的潜在靶点。该文就肽类和非肽类UⅡ受体拮抗剂的特点及其在心脑血管疾病、糖尿病、糖尿病肾病和高血压病等疾病的研究进展予以综述。Known as a substance with the most powerful vasoeonstrietor,urotensin II （U II ）and uroten- sin II receptor（UT） consisted system plays a significant role in the pathophysiology of many diseases. U III/UT system distribute in lots of organs such as;central nervous system, cardiovascular system,pancreas and kidney and so on. Thus a large number of researchers think that the antagonist of UT will be a new and potential target to treat many illnesses. Here is to make a review of the characteristic of the antagonist of UT in two big speeies：peptide and non-peptide,and their use in the research of diabetes, diabetic nephropathy,and hyper- tension etc..

关 键 词：尾加压素Ⅱ 尾加压素Ⅱ受体 拮抗剂 

分 类 号：R587[医药卫生—内分泌]